News Overview

The company’s revenue for the quarter registered a growth of 12.40% on a sequential basis to ₹2,982.40 Crore as compared to ₹2,653 Crore.

The bank announced that its Net Interest Margin witnessed an improvement of 4 basis points to 3.97% on a sequential basis.

The renewal premium, as per the company, was up by 12.90% YoY to ₹14,680.30 Crore versus ₹13,003.20 Crore.

Here are some of the stocks that may see significant price movement today: Axis Bank, Tech Mahindra, SBI Card & Payments.

The company's net profit in Q4FY25 came in nearly 8% higher at ₹15,367.92 lakh as compared to the corresponding quarter in the previous year at ₹14,261.53 lakh.

EBITDA margin narrowed by 250 basis points to 13.5%, due to increased input and operating costs.

TMB continues to focus on retail and MSME customer franchise, particularly in south India, where it enjoys a strong regional franchis

The drug is the generic alternative of the Vitamin K1 Injection produced by Hospira Inc and is indicated in the treatment of Vitamin K deficiency-related coagulation disorders.

The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.

The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.